683 results about "Pulmonary artery" patented technology

Devices, systems and methods are disclosed for the formation of an arteriovenous fistula. Embodiments include catheter apparatus including an ablation element for creating and / or modifying the fistula. The devices, systems and methods can be used to treat patients with one or more numerous ailments including chronic obstructive pulmonary disease, congestive heart failure, hypertension, hypotension, respiratory failure, pulmonary arterial hypertension, lung fibrosis and adult respiratory distress syndrome.

A cannulation system for cardiac support uses an inner cannula disposed within an outer cannula. The outer cannula includes a fluid inlet for placement within the right atrium of a heart. The inner cannula includes a fluid inlet extending through the fluid inlet of the outer cannula and the atrial septum for placement within at least one of the left atrium and left ventricle of the heart. The cannulation system also employs a pumping assembly coupled to the inner and outer cannulas to withdraw blood from the right atrium for delivery to the pulmonary artery to provide right heart support, or to withdraw blood from at least one of the left atrium and left ventricle for delivery into the aorta to provide left heart support, or both.

A delivery method and system for noninvasively monitoring cardiac physiologic parameters used to evaluate patients with cardiovascular conditions. The system includes an implantable sensing device configured for chronic implantation in a cavity of the cardiovascular system, such as the heart, pulmonary artery (PA), etc. The method involves introducing the sensing device through a cardiovascular cavity that is upstream in the vasculature from the cavity where implantation is intended and has a larger diameter than the intended cavity, and thereafter blood flow through the cardiovascular system delivers the device to the intended cavity. The device is sized and configured so as to secure itself within the intended cavity when the device moves through the cavity to a point where the diameter narrows sufficiently to secure the device and so as to be oriented once secured to sense a pressure either within, upstream (wedge), or downstream (distal) of the cavity.

The invention relates to a novel percutaneous aortic valve and pulmonary valve exchanger, which is a self-expand support with biological valve, formed by the support in special shape and made from nickel titanium alloy skeleton and the three-blade one-way opening valve formed by pig heart, wherein, the support has fixing and supporting functions, and the pig heart forms three valves fixed in the support. The invention has little hurt, high safety and reduced complication.

The present invention features methods for treating, stabilizing, preventing, and / or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and / or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and / or nanoparticles that comprise a carrier protein and a taxane (e.g. paclitaxel) or a derivative thereof.

A tiny electrically powered hydrodynamic blood pump is disclosed which occupies one third of the aortic or pulmonary valve position, and pumps directly from the left ventricle to the aorta or from the right ventricle to the pulmonary artery. The device is configured to exactly match or approximate the space of one leaflet and sinus of valsalva, with part of the device supported in the outflow tract of the ventricular cavity adjacent to the valve. In the configuration used, two leaflets of the natural tri-leaflet valve remain functional and the pump resides where the third leaflet had been. When implanted, the outer surface of the device includes two faces against which the two valve leaflets seal when closed. To obtain the best valve function, the shape of these faces may be custom fabricated to match the individual patient's valve geometry based on high resolution three dimensional CT or MRI images. Another embodiment of the invention discloses a combined two leaflet tissue valve with the miniature blood pump supported in the position usually occupied by the third leaflet. Either stented or un-stented tissue valves may be used. This structure preserves two thirds of the valve annulus area for ejection of blood by the natural ventricle, with excellent washing of the aortic root and interface of the blood pump to the heart. In the aortic position, the blood pump is positioned in the non-coronary cusp. A major advantage of the transvalvular VAD is the elimination of both the inflow and outflow cannulae usually required with heart assist devices.

This inventions relates to compounds having the structure Formula Iand pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

Endoscopic poses are used to indicate the exact location and direction in which a physician must orient the endoscope to sample a region of interest (ROI) in an airway tree or other luminal structure. Using a patient-specific model of the anatomy derived from a 3D MDCT image, poses are chosen to be realizable given the physical characteristics of the endoscope and the relative geometry of the patient's airways and the ROI. To help ensure the safety of the patient, the calculations also account for obstacles such as the aorta and pulmonary arteries, precluding the puncture of these sensitive blood vessels. A real-time visualization system conveys the calculated pose orientation and the quality of any arbitrary bronchoscopic pose orientation. A suggested pose orientation is represented as an icon within a virtual rendering of the patient's airway tree or other structure. The location and orientation of the icon indicates the suggested pose orientation to which the physician should align during the procedure.

Ultrasound energy originating from an emitter at a number of predetermined positions is sensed by a plurality of duplex transducers in a predefined arrangement. Each transducer produces a sensor signal representing ultrasound energy sensed by it, and the sensor signals of each transducer are stored in association with the predetermined position producing the sensor signal. Thereafter, an ablation pattern corresponding to a group of the predetermined positions may be generated by actuating each transducer with a time-reversed version of the sensor signals stored in association with the group of positions. By placing the transducers in a predetermined spatial relationship to the heart, the ablation pattern may be formed on the ostium of a pulmonary artery. Preferably the predetermined positions correspond to a grid of dots that may be used to approximate virtually any shape.

Methods for using blood pumps to treat heart failure are disclosed. The pump is mounted on an interior of a stent, and the stent is releasably mounted on a distal end of a catheter. The distal end of the catheter is inserted into a peripheral artery and advanced to position at a region of interest within the descending aorta, the ascending aorta, or the left ventricle. The stent and the pump are released from the catheter, and the pump is activated to increase blood flow downstream of the pump. The pump can also be positioned in the vena cava or used to treat right-sided heart failure following the insertion of an LVAD, or to improve venous return in patients with varicose veins. Non-stent pumps are described for insertion between the pulmonary vein and aorta, and between the vena cava and pulmonary artery designed for use during cardiac surgery.

Methods and systems of maintaining, evaluating, and providing therapy to a lung ex vivo. The methods and systems involve positioning the lung in an ex vivo perfusion circuit; circulating a perfusion fluid through the lung, the fluid entering the lung through a pulmonary artery interface and leaving the lung through a left atrial interface; and ventilating the lung by flowing a ventilation gas through a tracheal interface. Maintaining the lung for extended periods involves causing the lung to rebreath a captive volume of air, and reaching an equilibrium state between the perfusion fluid and the ventilation gas. Evaluating the gas exchange capability of the lung involves deoxygenating the perfusion fluid and measuring a time taken to reoxygenate the perfusion fluid by ventilating the lung with an oxygenation gas.

Sensors located on a sensor carrier are placed adjacent one or more of a surgical patient's major thoracic blood-containing structures such as the aorta or pulmonary artery, and characteristics of blood in the blood-containing structures are determined noninvasively by measuring transmission or reflection of light or other types of energy by the blood. Emitters and receptors included in the sensors are connected electrically with suitable electronic signal generating and processing components in a package remote from the sensor carrier.

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

Microparticles comprising iloprost are disclosed. In some embodiments, the microparticles are used to treat pulmonary hypertension. Devices comprising the microparticles are also disclosed. Combination therapies utilizing the microparticles are also provided.

This inventions relates to compounds having the structure Formula Iand pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and / or preventing pulmonary arterial hypertension and / or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT2A antagonists, such as sarpogrelate, selective serotonin reuptake inhibitors, such as fluoxetine, statins, and vascular remodeling modulators, such as Gleevec.

This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and / or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, nonalcoholic fatty liver disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

A method and apparatus for determining cardiac parameters within the body of a patient includes a wireless sensor positioned in the patient's pulmonary artery. An external RF telemetry device communicates wirelessly with the sensor and interrogates the sensor to determine changes in pressure in the pulmonary artery over time. The peak pressure difference is determined. Then, assuming zero blood flow velocity at the time of valve opening and at the time of valve closing, a velocity-time function is determined. The velocity-time function is used to determine a velocity-time integral. The velocity-time integral is then used to determine cardiac stroke volume. The cardiac stroke volume is multiplied times the heartbeat rate to determine cardiac output. The cardiac output can be monitored over time to determine continuous cardiac output.

Minimally invasive systems and methods are described for measuring pulmonary circulation information from the pulmonary arteries. A transbronchial Doppler ultrasound catheter is advanced through the airways and in the vicinity of the pulmonary artery. Doppler ultrasound energy is sent through the airway wall and across the pulmonary artery to obtain velocity information of blood flowing through the artery. The velocity information is used to compute pulmonary circulation information including but not limited to flowrate.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

A method for monitoring a right atrial pressure (RAP) and a left atrial pressure (LAP) for diagnosis of a heart condition includes positioning a transseptal device with respect to a pulmonary artery to monitor at least one flow characteristic of blood through the pulmonary artery. The transseptal device is configured to generate one or more signals representative of the at least one flow characteristic. A right ventricular end diastolic pressure (RVEDP) and a left ventricular end diastolic pressure (LVEDP) are detected to facilitate monitoring the heart condition.

At least one aspect of the invention is directed to a pump system for pumping blood though a body passageway. The pump system includes a distal section having at least one inlet to receive blood, a pumping section in fluid communication with the distal section to receive blood from the distal section, and a pump constructed and arranged to be positioned within the pumping section to draw blood into the pumping section in a first phase of operation and to pump blood out of the at least one outlet valve in a second phase of operation. The pump system may be configured such that the at least one inlet is in fluid communication with the pumping section in both the first phase of operation and the second phase of operation. At least one other aspect of the invention is directed to a pump system for pumping blood from one of the right atrium and the right ventricle to the pulmonary artery.

The present invention is directed to a method of screening for a therapeutic agent useful for treating pulmonary hypertension comprising: contacting an erythrocyte with a candidate therapeutic agent; and detecting a presence or absence of erythrocyte-derived adenosine triphosphate, wherein a greater erythrocyte-derived adenosine triphosphate level indicates the candidate therapeutic agent has greater activity in treating pulmonary hypertension. Additionally, the present invention is directed to methods of treating pulmonary arterial hypertension by stimulating ATP release from erythrocytes through co-administration to a subject in need thereof an amount of a PDE5 inhibitor compound, and an amount of a prostacyclin compound.

Methods and systems of maintaining, evaluating, and providing therapy to a lung ex vivo. The methods and systems involve positioning the lung in an ex vivo perfusion circuit; circulating a perfusion fluid through the lung, the fluid entering the lung through a pulmonary artery interface and leaving the lung through a left atrial interface; and ventilating the lung by flowing a ventilation gas through a tracheal interface. Maintaining the lung for extended periods involves causing the lung to rebreath a captive volume of air, and reaching an equilibrium state between the perfusion fluid and the ventilation gas. Evaluating the gas exchange capability of the lung involves deoxygenating the perfusion fluid and measuring a time taken to reoxygenate the perfusion fluid by ventilating the lung with an oxygenation gas.